Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) profit net of tax attributable to owners of the parent was up 8% year over year to 146.1 million yuan in the third quarter of the year from 135.7 million yuan, according to a filing with the Singapore Exchange on Wednesday.
Earnings per share came in at 0.19 yuan compared with 0.17 yuan in the year-ago period.
Revenue was down 3% year over year to 1.65 billion yuan from 1.70 billion yuan, mainly due to a decrease in commercial sales.
Shares of the pharmaceutical company were down nearly 2% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。